These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 31774211)
1. Combretastatin analogues in cancer biology: A prospective view. Sherbet GV J Cell Biochem; 2020 Mar; 121(3):2127-2138. PubMed ID: 31774211 [TBL] [Abstract][Full Text] [Related]
2. Suppression of angiogenesis and tumour progression by combretastatin and derivatives. Sherbet GV Cancer Lett; 2017 Sep; 403():289-295. PubMed ID: 28688972 [TBL] [Abstract][Full Text] [Related]
3. Combretastatin-based compounds with therapeutic characteristics: a patent review. Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715 [No Abstract] [Full Text] [Related]
4. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism. Hori K Cancer Metastasis Rev; 2012 Jun; 31(1-2):109-22. PubMed ID: 22101805 [TBL] [Abstract][Full Text] [Related]
5. The biology of the combretastatins as tumour vascular targeting agents. Tozer GM; Kanthou C; Parkins CS; Hill SA Int J Exp Pathol; 2002 Feb; 83(1):21-38. PubMed ID: 12059907 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4. Guan Q; Yang F; Guo D; Xu J; Jiang M; Liu C; Bao K; Wu Y; Zhang W Eur J Med Chem; 2014 Nov; 87():1-9. PubMed ID: 25233100 [TBL] [Abstract][Full Text] [Related]
7. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth. Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355 [TBL] [Abstract][Full Text] [Related]
8. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status. Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966 [TBL] [Abstract][Full Text] [Related]
9. Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity. Medarde M; Maya AB; Pérez-Melero C J Enzyme Inhib Med Chem; 2004 Dec; 19(6):521-40. PubMed ID: 15662956 [TBL] [Abstract][Full Text] [Related]
10. OMA1520 and OMA1774, novel 1,2,4-triazole bearing analogs of combretastatin A-4, inhibit hepatocellular carcinoma: Histological and immunohistochemical studies. Nofal AE; Shatla IM; Abdelhafeez DA; Mustafa M; Aly OM Biomed Pharmacother; 2021 Jun; 138():111417. PubMed ID: 33752057 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel alkylsulfanyl-1,2,4-triazoles as cis-restricted combretastatin A-4 analogues. Li YH; Zhang B; Yang HK; Li Q; Diao PC; You WW; Zhao PL Eur J Med Chem; 2017 Jan; 125():1098-1106. PubMed ID: 27810596 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of pironetin analogue/combretastatin A-4 hybrids containing a 1,2,3-triazole ring and evaluation of their cytotoxic activity. Vilanova C; Torijano-Gutiérrez S; Díaz-Oltra S; Murga J; Falomir E; Carda M; Alberto Marco J Eur J Med Chem; 2014 Nov; 87():125-30. PubMed ID: 25240870 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340 [TBL] [Abstract][Full Text] [Related]
14. Combretastatins D-3 and D-4, new macrocyclic lactones from Getonia floribunda. Vongvanich N; Kittakoop P; Charoenchai P; Intamas S; Danwisetkanjana K; Thebtaranonth Y Planta Med; 2005 Feb; 71(2):191-3. PubMed ID: 15729632 [TBL] [Abstract][Full Text] [Related]
15. New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents. Mahal K; Biersack B; Schobert R Int J Clin Pharmacol Ther; 2013 Jan; 51(1):41-3. PubMed ID: 23259996 [No Abstract] [Full Text] [Related]
16. Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents. Patil PO; Patil AG; Rane RA; Patil PC; Deshmukh PK; Bari SB; Patil DA; Naphade SS Anticancer Agents Med Chem; 2015; 15(8):955-69. PubMed ID: 26007283 [TBL] [Abstract][Full Text] [Related]
18. Influence of charge transfer on the isomerisation of stilbene derivatives for application in cancer therapy. Holzmann N; Bernasconi L; Bisby RH; Parker AW Phys Chem Chem Phys; 2018 Nov; 20(44):27778-27790. PubMed ID: 30378611 [TBL] [Abstract][Full Text] [Related]
19. The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design. Giacomini E; Rupiani S; Guidotti L; Recanatini M; Roberti M Curr Med Chem; 2016; 23(23):2439-89. PubMed ID: 27183980 [TBL] [Abstract][Full Text] [Related]